Assessments of TCR redirected human T cells in immunodeficient mice injected with human WT1 expressing tumour cells have previously demonstrated the potency of retroviral modified T cells in vivo, including T cell homing and tumour eradication. This evidence concerns the gene WT1 and neoplasm.